Impairment of the executive attention network in premenopausal women with hormone receptor-positive breast cancer treated with tamoxifen

Chen, Xingui; Li, Jingjing; Zhang, Jingjie; He, Xiaoxuan; Zhu, Chunyan; Zhang, Lei; Hu, Xinglong; Wang, Kai

doi:10.1016/j.psyneuen.2016.10.020

Cited by 17 publications

(25 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We classified seven studies as considering attention an outcome and a cognitive domain possibly affected by the use of tamoxifen. These studies included objective measures that assess attention and concentration, 16,23 visual attention, 16,18,33,38,39 and distractibility 31 . The results of the studies investigating attention and concentration, visual attention, and distractibility generally suggested that tamoxifen does not negatively affect those skills 16,18,23,31,38,39 .…”

Section: Resultsmentioning

confidence: 99%

“…These studies included objective measures that assess attention and concentration, 16,23 visual attention, 16,18,33,38,39 and distractibility 31 . The results of the studies investigating attention and concentration, visual attention, and distractibility generally suggested that tamoxifen does not negatively affect those skills 16,18,23,31,38,39 . In fact, one study 38 suggested that women taking tamoxifen performed significantly better in tasks of attention/concentration compared to women taking AIs and also to women taking tamoxifen followed by AIs.…”

Section: Resultsmentioning

confidence: 99%

“…Studies that considered short‐term memory included immediate verbal 16,18,19,25,30,31,33–37,40 and visual 16,18,19,25,30,31,34,38,41 memory. Furthermore, 13 studies included working memory 16,18,19,30–35,38–40 . Results of the majority of these studies suggested that tamoxifen does not affect the performance of women with breast cancer in tasks of long‐term memory, working memory, and visual short‐term memory.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Effects of tamoxifen on cognition and language in women with breast cancer: A systematic search and a scoping review

et al. 2021

View full text Add to dashboard Cite

Objective Breast cancer treatments bring adverse consequences that interfere with everyday functioning. Importantly, some of these treatments are associated with cognitive and language changes. Tamoxifen is a selective estrogen receptor modulator and is a common endocrine therapy treatment for breast cancer. The current review examines the specific domains of cognition and language affected by the use of tamoxifen in women with breast cancer. Methods We conducted a systematic search that examined cognitive and/or language functions in chemotherapy‐naïve women with breast cancer taking tamoxifen. PubMed, Cochrane CENTRAL, CINAHL Complete, PsycINFO, Scopus, EMBASE, and the Grey Literature Report (http://greylit.org) were searched. Covidence Systematic Review software (http://covidence.org) was used to manage the screening process of study titles and abstracts as well as full texts. A total of 17 studies were included in the review. Results A range of cognitive and language domains were reported. These were grouped into seven broad domains: attention, memory, speed, executive functioning, verbal abilities, visual abilities, and language abilities. Results showed that there is compelling evidence that specific domains of memory and speed are negatively affected by the use of tamoxifen. In addition, there was a pattern of change in domains of executive functions and verbal abilities. Conclusions Tamoxifen affects specific cognitive and language domains. Language domains beyond semantics have not been studied and thus conclusions related to these domains, and language in general, could not be made. Studies exploring the effects of tamoxifen on the different domains of language are recommended.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Effects of tamoxifen on cognition and language in women with breast cancer: A systematic search and a scoping review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, there are numerous small-sized studies that seem to suggest that tamoxifen could cause cognitive impairments in breast cancer patients. Indeed, Chen and coworkers [142] were able to detect impairment of the attention network and deficit in executive function performance in 43 premenopausal women with breast cancer exposed to 20 mg/day tamoxifen, whereas Boele and collaborators [143] found lower scores in verbal memory among 20 tamoxifen postmenopausal users.…”

Section: Endocrine Therapymentioning

confidence: 99%

Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients

Natale¹,

Bocci²

2019

Brain and Heart Dynamics

View full text Add to dashboard Cite

“… 13-17 While the literature on the long-term cognitive effects of hormonal therapy is quite sparse compared to that of chemotherapy, the studies that have investigated this question have reported a negative influence of hormonal therapy on cognition in breast cancer patients. 18-20 It has been shown that hormonal therapy can lead to organizational, activational, neurotropic, and neuroprotective deficits in breast cancer survivors. 21 There is substantial evidence that estrogen, which is blocked in hormonal based therapies, modulates cognitive functioning (see Shilling et al .…”

Section: Introductionmentioning

confidence: 99%

Cancer-related cognitive impairment in breast cancer survivors: An examination of conceptual and statistical cognitive domains using principal component analysis

Lambert¹,

Ouimet²,

Wan³

et al. 2018

Oncol Rev

View full text Add to dashboard Cite

There is a great deal of variability in the composition of neuropsychological test batteries used in the assessment of cancerrelated cognitive impairment (CRCI). Not only the development of a gold standard approach for CRCI assessment would allow for easier identification of women suffering from CRCI but it would also promote optimal care for survivors. As a first step towards the development of a valid and reliable unified test battery, the objective of this study was to verify whether the theoretical domains commonly used in CRCI assessment are statistically supported, before and after breast cancer treatment. Principal component analyses (PCA) were performed on the results from 23 neuropsychological tests grouped into eight conceptual domains. For baseline data, the Kaiser-Meyer-Olkin was .82 and Bartlett’s X2(253, N=95) = 949.48, P<0.001. A five-component solution explained 60.94% of the common variance. For the post-treatment data, the Kaiser-Meyer-Olkin was .83 and Bartlett’s X2(253, N=95) = 1007.21, P<0.001 and a five component solution explained 62.03% of the common variance. Although a visual comparison of the theoretical model with those determined via PCA indicated important overlap between conceptual domains and statistical components, significant dissimilarities were also observed.

show abstract

Impairment of the executive attention network in premenopausal women with hormone receptor-positive breast cancer treated with tamoxifen

Cited by 17 publications

References 40 publications

Effects of tamoxifen on cognition and language in women with breast cancer: A systematic search and a scoping review

Effects of tamoxifen on cognition and language in women with breast cancer: A systematic search and a scoping review

Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients

Cancer-related cognitive impairment in breast cancer survivors: An examination of conceptual and statistical cognitive domains using principal component analysis

Contact Info

Product

Resources

About